Skip to main content
TipRanks
Go Ultimate75% OFF

D.Western Therapeutics Institute (6DW) AI Stock Analysis

0 Followers
DE:6DW

D.Western Therapeutics Institute

(Frankfurt:6DW)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Narrowing lossesLosses narrowed materially in 2025 versus 2024, showing some operating improvement despite continued unprofitability. If sustained, this trajectory could reduce the funding burden, improve capital efficiency, and move the drug-development platform closer to a viable earnings base.
Negative Factors
Persistent cash burnOperating and free cash flow were negative in every year shown, so operations have not yet funded themselves. Although 2025 burn improved materially versus 2024, continued negative FCF can require external financing and constrain investment in drug candidates over the next several quarters.

D.Western Therapeutics Institute (6DW) vs. iShares MSCI Germany ETF (EWG)

-60%-50%-40%-30%-20%-10%0%10%20%DE:6DW-56.86%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 15.73M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-4.1
Beta (1Y)
-0.49
Revenue Growth
-69.15%
EPS Growth
58.91%
Country
Germany
Employees
19
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

D.Western Therapeutics Institute Business Overview & Revenue Model

Company Description

D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed...

D.Western Therapeutics Institute Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:6DW against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4978JP:497842NeutralJPY 11.43B-24.60――-8.23%-48.10%
JP:4592JP:459239UnderperformJPY 65.10B-17.48-37.79%――5.71%
JP:4593JP:459339UnderperformJPY 29.55B-13.16――-51.55%52.19%
JP:4599JP:459938UnderperformJPY 7.65B-4.11―――4.85%
JP:7776JP:777626UnderperformJPY 6.42B-5.26――-49.43%-3.77%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%20%DE:6DWJP:4592JP:4593JP:4599JP:4978JP:7776Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:6DW and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:6DWD.Western Therapeutics Institute, Inc.0.22-0.28-55.65%
JP:4592SanBio Co 834.00-1556.00-65.10%
JP:4593Healios KK218.00-233.00-51.66%
JP:4599StemRIM Inc.122.00-154.00-55.80%
JP:4978ReproCELL Inc.107.00-53.00-33.13%
JP:7776CellSeed Inc.162.00-222.00-57.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.